Projects per year
Abstract
Allosteric modulation of G protein-coupled receptors (GPCRs) is a major paradigm in drug discovery. Despite decades of research, a molecular-level understanding of the general principles that govern the myriad pharmacological effects exerted by GPCR allosteric modulators remains limited. The M4 muscarinic acetylcholine receptor (M4 mAChR) is a validated and clinically relevant allosteric drug target for several major psychiatric and cognitive disorders. In this study, we rigorously quantified the affinity, efficacy, and magnitude of modulation of two different positive allosteric modu-lators, LY2033298 (LY298) and VU0467154 (VU154), combined with the endogenous agonist acetyl-choline (ACh) or the high-affinity agonist iperoxo (Ipx), at the human M4 mAChR. By determining the cryo-electron microscopy structures of the M4 mAChR, bound to a cognate Gi1 protein and in complex with ACh, Ipx, LY298-Ipx, and VU154-Ipx, and applying molecular dynamics simulations, we determine key molecular mechanisms underlying allosteric pharmacology. In addition to delineating the contri-bution of spatially distinct binding sites on observed pharmacology, our findings also revealed a vital role for orthosteric and allosteric ligand–receptor–transducer complex stability, mediated by confor-mational dynamics between these sites, in the ultimate determination of affinity, efficacy, cooperativity, probe dependence, and species variability. There results provide a holistic framework for further GPCR mechanistic studies and can aid in the discovery and design of future allosteric drugs.
Original language | English |
---|---|
Article number | e83477 |
Number of pages | 52 |
Journal | eLife |
Volume | 12 |
DOIs | |
Publication status | Published - 30 May 2023 |
-
ARC Industrial Transformation Training Centre for Cryo-Electron Microscopy of Membrane Proteins for Drug Discovery
Sexton, P. (Primary Chief Investigator (PCI)), Rouiller, I. (Chief Investigator (CI)), Wootten, D. (Chief Investigator (CI)), van Oijen, A. (Chief Investigator (CI)), Parker, M. W. (Chief Investigator (CI)), Lucet, I. (Partner Investigator (PI)), Griffin, M. (Chief Investigator (CI)), Adams, D. J. (Chief Investigator (CI)), Czabotar, P. E. (Partner Investigator (PI)), Flocco, M. (Partner Investigator (PI)), Han, S. (Partner Investigator (PI)), Shepherd, R. (Partner Investigator (PI)), Ciferri, C. (Partner Investigator (PI)), Williams, P. A. (Partner Investigator (PI)), Brown, D. (Partner Investigator (PI)), Schreuder, H. (Partner Investigator (PI)), Reedtz-Runge, S. (Partner Investigator (PI)), Drinkwater, C. (Partner Investigator (PI)), Howard, B. L. (Partner Investigator (PI)), Betigeri, G. (Partner Investigator (PI)), Pryor, E. (Partner Investigator (PI)), How, J. (Project Manager) & Christopoulos, T. (Chief Investigator (CI))
Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom)
23/03/21 → 23/03/27
Project: Research
-
Using protein structure and dynamics to facilitate drug discovery
Thal, D. (Primary Chief Investigator (PCI))
1/01/21 → 31/12/25
Project: Research
-
Discovering novel allosteric probes of muscarinic acetylcholine receptors
Valant, C. (Primary Chief Investigator (PCI)), Scammells, P. (Chief Investigator (CI)) & Christopoulos, A. (Chief Investigator (CI))
3/06/19 → 31/12/22
Project: Research
Equipment
-
High-performance Computing (M3/MASSIVE)
Powell, D. (Manager) & Tan, G. (Manager)
Office of the Vice-Provost (Research and Research Infrastructure)Facility/equipment: Facility
-
Ramaciotti Centre for Cryo-Electron Microscopy (CryoEM)
Ramm, G. (Manager), Crawford, S. A. (Operator), Venugopal, H. (Operator), Clark, J. M. (Operator) & Gervinskas, G. (Operator)
Faculty of Medicine Nursing and Health Sciences Research PlatformsFacility/equipment: Facility